New psoriasis drug shows promise in early trial
NCT ID NCT07090330
First seen Oct 01, 2025 · Last updated May 08, 2026 · Updated 26 times
Summary
This study tests an experimental drug called ORKA-001 in 80 adults with moderate-to-severe plaque psoriasis. Participants receive either the drug or a placebo to see if it can clear skin lesions. The main goal is to measure complete skin clearance at 16 weeks using a standard psoriasis severity score.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oruka Therapeutics Investigative Site
Fountain Valley, California, 92708, United States
-
Oruka Therapeutics Investigative Site
Los Angeles, California, 90045, United States
-
Oruka Therapeutics Investigative Site
San Diego, California, 92123, United States
-
Oruka Therapeutics Investigative Site
Santa Ana, California, 92701, United States
-
Oruka Therapeutics Investigative Site
Santa Monica, California, 90404, United States
-
Oruka Therapeutics Investigative Site
Cromwell, Connecticut, 06416, United States
-
Oruka Therapeutics Investigative Site
Coral Gables, Florida, 33134, United States
-
Oruka Therapeutics Investigative Site
Rolling Meadows, Illinois, 60008, United States
-
Oruka Therapeutics Investigative Site
Bowling Green, Kentucky, 42104, United States
-
Oruka Therapeutics Investigative Site
Rockville, Maryland, 20850, United States
-
Oruka Therapeutics Investigative Site
Boston, Massachusetts, 02111, United States
-
Oruka Therapeutics Investigative Site
Detroit, Michigan, 48202, United States
-
Oruka Therapeutics Investigative Site
New York, New York, 10023, United States
-
Oruka Therapeutics Investigative Site
New York, New York, 10029, United States
-
Oruka Therapeutics Investigative Site
Portland, Oregon, 97201, United States
-
Oruka Therapeutics Investigative Site
Norfolk, Virginia, 23502, United States
-
Oruka Therapeutics Investigative Site
Milwaukee, Wisconsin, 53226, United States
-
Oruka Therapeutics Investigative Site
Edmonton, Alberta, T5J 3S9, Canada
-
Oruka Therapeutics Investigative Site
Edmonton, Alberta, T6G 1C3, Canada
-
Oruka Therapeutics Investigative Site
Surrey, British Columbia, V3R 6A7, Canada
-
Oruka Therapeutics Investigative Site
Hamilton, Ontario, L8N 1Y2, Canada
-
Oruka Therapeutics Investigative Site
London, Ontario, N6H 5LS, Canada
-
Oruka Therapeutics Investigative Site
Markham, Ontario, L3P 1X3, Canada
-
Oruka Therapeutics Investigative Site
Peterborough, Ontario, K9J 5K2, Canada
-
Oruka Therapeutics Investigative Site
Toronto, Ontario, M4W 2N4, Canada
-
Oruka Therapeutics Investigative Site
Waterloo, Ontario, N2J 1C4, Canada
Conditions
Explore the condition pages connected to this study.